Exact Sciences – Multi-Cancer Earlier Detection

Screening and earlier detection are key in the fight against cancer. Exact Sciences is at the forefront of multi-cancer earlier detection, which has the power to close the screening gap and to get at that 70% of cancers that currently do not have routine screening options. Jake Orville, General Manager of Pipeline at Exact Sciences, shares his perspective on the latest innovations in multi-cancer earlier detection and other emerging technologies and talks about Exact Sciences’ proprietary testing platform, which can identify the minute fragments of circulating tumor DNA and proteins expressed that are causative across many types of cancer. 

Read More

NantHealth – NaviNet and the No Surprises Act

Christina Perkins, Vice President of Product Management & Strategy for NaviNet discusses news surrounding the No Surprises Act requirements and deadlines. She talks about NantHealth’s NaviNet that gives providers an easy way to enter information necessary for payers to process an explanation of benefits (EOB) request. It’s an easy way for the payers and providers to collaborate and electronically document the info needed so all parties involved in the patient’s care understand the cost estimate and therefore recommend the appropriate level of care. NaviNet also ensures that provider directory info is reviewed and up-to-date.

Read More

Traveling and Overactive Bladder

Holiday season is right around the corner and for people living with overactive bladder, it can cause a lot of stress and anxiety about visiting family or friends, traveling and even avoiding certain holiday  meals that can irritate the bladder.   In this segment, Diane Newman, a nurse practitioner specializing in urology and a spokesperson for Urovant Sciences discusses overactive bladder and offers tips to help manage this common condition.

Read More

Little Known But Widespread Virus – Leading Infectious Cause of Birth Defects in the US

Dr. Lori Panther, MD, MPH, Vice President of Clinical Development, Infectious Diseases at Moderna discusses a virus that is the leading infectious cause of birth defects in the US called CMV or cytomegalovirus which has no vaccine. She talks about the current research on a CMV vaccine. She is joined by Shayne Gaffney, parent of a child with CMV who is bringing awareness to the illness and his goal is to push for universal CMV screening…and educate other parents about the virus. 

Read More

Commitment of Nurse Practitioners Amid Backdrop of COVID-19 Pandemic

April N. Kapu, President, American Association of Nurse Practitioners ® and certified acute care nurse practitioner (NP) discusses the purpose of National Nurse Practitioner Week, November 7-13, the dedication and commitment of NPs during the last year and a half treating COVID patients and how the role and responsibilities of NPs evolved during the pandemic. She talks about the nursing shortage and what can be/is being done to help draw new nurses and NPs into the profession. 

Read More

Foundation for Women’s Cancer – Educating Patients

Dr. Lisa Barroilhet, Associate Professor in the department of Obstetrics and Gynecology at the University of Wisconsin School of Medicine and Public Health discusses the launch of the program #MoveTheMessage making educational materials available to patients, and giving access to medical professionals to use the materials and direct patients to them. A survey of gynecologic oncologists found that most felt that access to patient education materials is an important part of patient outcomes and feel that there is a great need for access to online educational resources.

Read More

Debunking the Standard Approach to Monitoring Heart Disease

In this episode, Dr. James “Jim” K. Min, CEO of  Cleerly Health, a company whose mission is to up level the standard approaches to monitoring heart disease that have been used for decades, discusses its advanced non-invasive CT imaging. The advanced imaging allows physicians to monitor and characterize atherosclerosis (plaque) buildup, the primary disease that  causes heart attacks, to accurately determine a patient’s risk of a heart attack.  Dr. Min shares how this approach is more effective and efficient compared to historical manual tests, how  it is  helping patients identify their cardiovascular diseases and develop a treatment plan and how the healthcare system needs to use advanced imaging to prevent heart disease, similar to how it’s done in cancer care.   

Read More

Seqirus – FLUCELVAX QUADRIVALENT Approved for Children As Young as Six Months Old

Returning guest, Dave Ross, Vice President, Commercial Operations, North America at Seqirus discusses the FDA approval of the first and only cell-based influenza vaccine in the U.S., FLUCELVAX QUADRIVALENT for an expanded age indication for children as young as six months old. As a global leader in influenza prevention, this approval reinforces Seqirus’ commitment to developing innovative influenza vaccine technologies to protect as many eligible people as possible, particularly those in vulnerable populations and especially considering the ongoing COVID-19 pandemic. 

Read More